Literature DB >> 22226204

Tim-3, a negative regulator of anti-tumor immunity.

Ana Carrizosa Anderson1.   

Abstract

T cell immunoglobulin-3 (Tim-3) was identified nearly 10 years ago as a negative regulator of IFN-γ-secreting CD4(+) T helper 1 and CD8(+) T cytotoxic 1 cells. Tim-3 is now classed with other inhibitory receptors, such as cytotoxic lymphocyte antigen-4 and programmed death-1 that are commonly referred to as immune checkpoint molecules. Recent studies have highlighted Tim-3 as an important player in the CD8(+) T cell exhaustion that takes place in chronic immune conditions such as chronic viral infection and cancer in both humans and experimental models. In addition to its role in exhausted T cells, recent data suggest that Tim-3 can further influence cancer outcome through its action on myeloid cells and cancer stem cells.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22226204     DOI: 10.1016/j.coi.2011.12.005

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  76 in total

Review 1.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

2.  RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.

Authors:  Audrey N Jajosky; James E Coad; Jeffrey A Vos; Karen H Martin; Jamie R Senft; Sharon L Wenger; Laura F Gibson
Journal:  Stem Cells Transl Med       Date:  2014-05-22       Impact factor: 6.940

3.  TIM-3 Genetic Variations Affect Susceptibility to Osteoarthritis by Interfering with Interferon Gamma in CD4+ T Cells.

Authors:  Shufeng Li; Yanjun Ren; Dayong Peng; Zhen Yuan; Shiying Shan; Huaqiang Sun; Xinfeng Yan; Hong Xiao; Guang Li; Haihan Song
Journal:  Inflammation       Date:  2015-10       Impact factor: 4.092

Review 4.  FOXOs in cancer immunity: Knowns and unknowns.

Authors:  Youcai Deng; Fangjie Wang; Tiffany Hughes; Jianhua Yu
Journal:  Semin Cancer Biol       Date:  2018-01-05       Impact factor: 15.707

Review 5.  Immunomodulatory therapy for melanoma: ipilimumab and beyond.

Authors:  Margaret K Callahan; Michael A Postow; Jedd D Wolchok
Journal:  Clin Dermatol       Date:  2013 Mar-Apr       Impact factor: 3.541

6.  Stimulation of Camel Polyclonal Antibody against Human T cell Immunoglobulin and Mucin 3.

Authors:  Vida Homayouni; Hossein Khanahmad; Mazdak Ganjalikhani-Hakemi; Mahdi Behdani; Pouria Ghasemi; Abbas Rezaei
Journal:  Iran J Biotechnol       Date:  2017-09-27       Impact factor: 1.671

7.  Expression and anatomical distribution of TIM-containing molecules in Langerhans cell sarcoma.

Authors:  Jingwei Li; Dayan Cao; Guoning Guo; Yuzhang Wu; Yongwen Chen
Journal:  J Mol Histol       Date:  2012-12-21       Impact factor: 2.611

Review 8.  The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.

Authors:  Neha Shah; Sabina Sandigursky; Adam Mor
Journal:  Bull Hosp Jt Dis (2013)       Date:  2017-05

Review 9.  The immunobiology of myeloid-derived suppressor cells in cancer.

Authors:  Morteza Motallebnezhad; Farhad Jadidi-Niaragh; Elmira Safaie Qamsari; Salman Bagheri; Tohid Gharibi; Mehdi Yousefi
Journal:  Tumour Biol       Date:  2015-11-26

10.  Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma.

Authors:  Chen Cai; Yi-Fan Xu; Zhen-Jie Wu; Qin Dong; Min-Yu Li; Jason C Olson; Yaron M Rabinowitz; Lin-Hui Wang; Yinghao Sun
Journal:  World J Urol       Date:  2015-08-08       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.